ArticleScientific reports2023
Characteristics of gut microbiota in patients with metabolic associated fatty liver disease.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Consecutive fecal microbiota transplantation for metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial.Gut microbes · 2025Trial
- Description of Dorea chungnamensis sp. nov., an Aerotolerant Anaerobe Isolated from Pig Feces.Current microbiology · 2026Article
- Association of gut microbiota with central blood pressure and pulse pressure amplification in community-dwelling Japanese adults: the Wakayama study.Journal of human hypertension · 2026Article
- Indole-3-Propionic Acid Alleviates Metabolic Dysfunction-Associated Fatty Liver Disease via AHR/AMPK Signaling Activation.Food science & nutrition · 2026Article
- Characterization of gut microbiome signatures in metabolic dysfunction associated steatotic liver disease.NPJ biofilms and microbiomes · 2026Article
- Lactobacillaceae in Acute and Chronic Liver Diseases: From Microbiota Modulation to Therapeutic Potential.Probiotics and antimicrobial proteins · 2026Review
- Article
- Hyperammonemia reduces the populations of beneficial lactobacilli and bifidobacteria, disrupting the metabolic balance of the gut microbiome in rats.Frontiers in microbiology · 2026Article
- The role of theFrontiers in microbiology · 2026Review
- Association of gut microbiota dietary index with MAFLD and the risk of liver fibrosis: the mediating effect of vitamins.Journal of nutritional science · 2026Article
- Review
- Gut microbiome composition and metabolic activity in metabolic-associated fatty liver disease.Virulence · 2025Article
- Mechanistic roles and intervention strategies involving gut microbiota, amino acid metabolism, and the tumor immune microenvironment in MAFLD-HCC progression.Clinical and experimental medicine · 2025Review
- Estrogenic Effect of Probiotics on Anxiety and Depression: A Narrative Review.International journal of molecular sciences · 2025Review
- Artificially fermented dark loose tea ameliorates metabolic-associated fatty liver disease by activating the PI3K/AKT signalling pathway and regulating gut microbiota dysbiosis.Food chemistry: X · 2025Article
- Role of gut microbiota and its functional products in prenatal alcohol-induced anxiety-like behavior.Progress in neuro-psychopharmacology & biological psychiatry · 2025Article
- Distinct Gut Microbiota Signatures Are Associated with Severity of Metabolic Dysfunction-Associated Steatotic Liver Disease in People with HIV.International journal of molecular sciences · 2025Article
- Dissecting the Genetic Correlations and Causal Effects of Gut Microbiota on Pan-Cancer Phenotype: Driven by Common Dietary Preferences.Food science & nutrition · 2025Article
- Gut microbiota in non-alcoholic fatty liver disease: Pathophysiology, diagnosis, and therapeutics.World journal of hepatology · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic associated fatty liver disease (MAFLD) is rising in incidence and is an increasingly common cause of cirrhosis and hepatocellular carcinoma (HCC). Alterations in the gut microbiota have been shown to correlate with the development and progression of MAFLD. However, little is known regarding differences in the gut microbiomes of MAFLD patients and healthy cohorts, and subgroups at the abnormal activity of hepatic enzymes in China. In this study, we enrolled 81 MAFLD patients and 25 healthy volunteers. The fecal microbiota was assessed using 16S rRNA gene sequencing and metagenomic sequencing. The results suggested that Ruminococcus obeum and Alistipes were most enriched in healthy individuals when compared with MAFLD patients. Microbe-set Enrichment Analysis (MSEA) results showed Dorea, Lactobacillus and Megasphaera are enriched in MAFLD group. We also found that Alistipes has negatively related to serum glucose (GLU), gamma-glutamyl transferase (GGT), and alanine aminotransferase (ALT). Moreover, the abundance of Dorea was found to be significantly overrepresented in the MAFLD patients and the degree of enrichment increased with the increasing abnormal liver enzyme. An increase in Dorea, combined with decreases in Alistipes appears to be characteristic of MAFLD patients. Further study of microbiota may provide a novel insight into the pathogenesis of MAFLD as well as a novel treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.